Lun Cai1, Lin Jiejie1, Yuying Hu1, Wei Chen1, Liping Wei1, Qianchao He2, Yueqiang Hu3. 1. Department of Encephalopathy, The first affiliated hosipital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Nanning, Guangxi 530000, People's Republic of China. 2. Department of Encephalopathy, The first affiliated hosipital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Nanning, Guangxi 530000, People's Republic of China. Electronic address: gxnn8ch@126.com. 3. Department of Encephalopathy, The first affiliated hosipital of Guangxi University of Chinese Medicine, No. 89-9 Dongge Road, Nanning, Guangxi 530000, People's Republic of China. Electronic address: 137463195@qq.com.
Abstract
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy and safety of modified Sini San (MSS) for poststroke depression (PSD). METHODS: Randomized controlled trials of MSS for PSD were identified in the Web of science, PsycINFO, World Cat, CNKI, VIP, Wanfang, DuXiu, and Embase databases according to the inclusion and exclusion criteria. RESULTS: In total, 7 trials with 548 patients were included in the review. The meta-analysis showed that MSS had superior effects to fluoxetine hydrochloride in terms of response rate in patients with PSD (relative risk (RR): 1.19, 95% confidence interval (CI) [1.10, 1.28], Z = 4.31, P < 0.0001). MSS may be more effective at reducing Hamilton depression rating scale (HAMD) scores and modified Edinburgh-Scandinavia stroke scale (SSS) scores than fluoxetine hydrochloride after 4 and 8 weeks of treatment. CONCLUSIONS: Our meta-analysis demonstrated that MSS appears to have excellent therapeutic effects on PSD and no serious adverse effects. However, due to the small sample sizes and low quality of the literature, studies with higher methodological quality, larger sample sizes, and placebo controls are recommended in future research on MSS in patients with PSD to enhance the strength of the evidence. Therefore, clinicians should be cautious in using this evidence to make clinical decisions.
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy and safety of modified Sini San (MSS) for poststroke depression (PSD). METHODS: Randomized controlled trials of MSS for PSD were identified in the Web of science, PsycINFO, World Cat, CNKI, VIP, Wanfang, DuXiu, and Embase databases according to the inclusion and exclusion criteria. RESULTS: In total, 7 trials with 548 patients were included in the review. The meta-analysis showed that MSS had superior effects to fluoxetine hydrochloride in terms of response rate in patients with PSD (relative risk (RR): 1.19, 95% confidence interval (CI) [1.10, 1.28], Z = 4.31, P < 0.0001). MSS may be more effective at reducing Hamilton depression rating scale (HAMD) scores and modified Edinburgh-Scandinavia stroke scale (SSS) scores than fluoxetine hydrochloride after 4 and 8 weeks of treatment. CONCLUSIONS: Our meta-analysis demonstrated that MSS appears to have excellent therapeutic effects on PSD and no serious adverse effects. However, due to the small sample sizes and low quality of the literature, studies with higher methodological quality, larger sample sizes, and placebo controls are recommended in future research on MSS in patients with PSD to enhance the strength of the evidence. Therefore, clinicians should be cautious in using this evidence to make clinical decisions.
Authors: Yifeng Zheng; Juping Zhang; Wanqing Huang; Linda L D Zhong; Neng Wang; Shengqi Wang; Bowen Yang; Xuan Wang; Bo Pan; Honglin Situ; Yi Lin; Xiaoyan Liu; Yafei Shi; Zhiyu Wang Journal: Front Pharmacol Date: 2021-11-29 Impact factor: 5.810